A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

Study Summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Conditions

Obesity

Interventions / Drugs

Tirzepatide Standard of Care

View on ClinicalTrials.gov ↗

Sponsor

LLY

Eli Lilly and Company

Diabetes/Oncology

C53/100

Study Details

Enrollment3000 participants

Primary Completion—

Lead SponsorEli Lilly and Company

Data Retrieved2026-04-11 02:55:33.866830+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.